Aktis Oncology starts Phase 1b trial for prostate cancer drug AKY-2519
Tweet Send to a Friend
Aktis Oncology Inc. (NASDAQ: AKTS) announced the initiation of a Phase 1b clinical trial for AKY-2519, a B7-H3 miniprotein radioconjugate ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
